medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2018, Number 1

<< Back Next >>

Arch Med Fam 2018; 20 (1)

FINDRISC FINnish Diabetes Risk Score Questionnaire for the Detection of Undiagnosed Diabetes and Pre-diabetes

González PAA, Ponce RER, Toro BF, Acevedo GO, Dávila MR

Language: Spanish
References: 25
Page: 5-13
PDF size: 280.45 Kb.


ABSTRACT

Objective: To evaluate the capacity of the FINDRISC questionnaire to detect the risk of developing prediabetes and diabetes in patients of a clinic in the south of Mexico City. Methods: descriptive and cross-sectional study. A non-probabilistic sampling was done for convenience. Patients without previous diagnosis of prediabetes or diabetes mellitus were included, the identification card and the FINDRISC questionnaire were applied. Sensitivity, specificity, positive and negative predictive values, and the Youden index curve Receiver Operating Characteristics (ROC) was determined. The SPSS version 22 and Epi-Info version 7 programs were used for the statistical analyzes. With a level of statistical significance of ‹0.05. Results: 125 patients were included with an average age of 49.9 ± 15.1 years. 39.2% were diagnosed with prediabetes and 9.6% with diabetes. 44.8% had scores ≥15 in FINDRISC. On the effectiveness to identify patients with diabetes mellitus and prediabetes, an optimal cut-off point ≥ 15 was obtained. The area under the curve for diabetes was 0.845 (95% CI: 0.708-0.983) and for prediabetes 0.743 (95% CI 0.651- 0.836). Conclusions: the questionnaire can be used as a simple and non-invasive screening tool to identify people at high risk of diabetes and prediabetes in adults.


REFERENCES

  1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalencia of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3):311–21.

  2. Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: a short report for the national screening committee. Health Technol Assess 2013; 17(35):1–90.

  3. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 Informe Final de Resultados. [Citado 2017 Sept 22]. Disponible en: http://oment.uanl.mx/ultimascifras- de-diabetes-en-mexico-ensanut-mc-2016/

  4. Gong W, Lu B, Yang Z, Ye W, Du Y, Wang M, et al. Early-stage atherosclerosis in newly diagnosed, untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Metab 2009; 35(6):458–62.

  5. Rosas GJ, Mesa PJ. Prediabetes. En: Síndrome Metabólico y Enfermedad Cardiovascular. González CA, Lavalle GF, Ríos GJ. México. Intersistemas Editores. 2009. 3º edición. P 269-281.

  6. Dawes D, Ashe M, Campbell K, Cave D, Elley CR, Kaczorowski J, et al. Preventing diabetes in primary care: a feasibility cluster randomized trial. Can J Diabetes. 2015 Apr.; 39(2):111-6.

  7. Smith-Marsh D. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance. Drugs Today (Barc). 2013 Aug.; 49(8):499-507.

  8. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al; Act now study. Prevention of diabetes with pioglitazone in act now: physiologic correlates. Diabetes. 2013; 62(11):3920-6.

  9. Brown N, Critchley J, Bogowicz P, Mayige M, Unwin N. Risk scores based on self-reported or available clinical data to detect undiagnosed type 2 diabetes: a systematic review. Diabetes Res Clin Pract. 2012; 98(3):369–85.

  10. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26(3):725–31.

  11. Salinero-Fort MA, Burgos-Lunar C, Lahoz C, Mostaza JM, Abánades-Herranz JC, Laguna- Cuesta F, et al. Performance of the Finnish Diabetes Risk Score and a Simplified Finnish Diabetes Risk Score in a community-based, cross- sectional programme for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in Madrid, Spain: the spredia-2 study. Plos one. 2016; 11(7): e0158489.

  12. García-Alcalá H, Genestier-Tamborero CN, Hirales-Tamez O, Salinas-Palma J, Soto-Vega E. Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, México Diabetes, Metab Syndr Obes: Targets and Therapy. 2012; 5:403-406.

  13. Gomez-Arbelaez D, Alvarado-Jurado L, Ayala-Castillo M, Forero-Naranjo L, Camacho PA, López- Jaramillo P. Evaluation of the Finnish Diabetes Risk Score to predict type 2 diabetes mellitus in a Colombian population: A longitudinal observational study. World J Diabetes. 2015; 6(17): 1337- 1344.

  14. Vandersmissen GJ, Godderis L. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) for diabetes screening in occupational health care. Int J Occup Med Environ Health. 2015; 28(3):587-91.

  15. Zhang L, Zhang Z, Zhang Y, Hu G, Chen L. Evaluation of Finnish Diabetes Risk Score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999–2010. PLoS One. 2014; 9(5):e97865.

  16. Getaneh A, Andres R, Brillon DJ, Findley SE. Hemoglobin A (1c) criterion for diabetes diagnosis among Hispanic and non-Hispanic populations. Endocr Pract. 2011; 17: 210–17.

  17. Soriguer F, Valdés S, Tapia MJ, Esteva I, Ruiz de Adana MS, et al. Validación del FINDRISC (FINnish Diabetes Risk Score) para la predicción del riesgo de diabetes tipo 2 en una población del sur de España. Estudio Pizarra Med Clin (Barc). 2012; 138(9): 371–376.

  18. Featherstone T, Eurich DT, Simpson SH. Limited Effectiveness of Diabetes Risk Assessment Tools in Seniors' Facility Residents. Value Health. 2017; 20(3):329-335.

  19. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011; 37(2):144–51.

  20. Štiglic G, Fijačko N, Stožer A, Sheikh A, Pajnkihar M. Validation of the Finnish Diabetes Risk Score (FINDRISC) questionnaire for undiagnosed type 2 diabetes screening in the Slovenian working population. Diabetes Res Clin Pract. 2016 Oct; 120:194-7.

  21. Barengo NC, Tamayo DC, Tono T, Tuomilehto J. A Colombian diabetes risk score for detecting undiagnosed diabetes and impaired glucose regulation. Prim Care Diabetes. 2017 Feb; 11(1):86-93.

  22. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao- Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376: 112-123

  23. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010; 362: 800-811

  24. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008; 168: 1699-1704.

  25. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 Suppl 1: S14-S80.




2020     |     www.medigraphic.com